A Phase 2 Study of Atengenal (A-10) and Astugenal (AS2-1) in Diffuse, Intrinsic Pontine Glioma (DIPG)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 02 Feb 2018
At a glance
- Drugs Antineoplaston A10/antineoplaston AS2-1 (Primary)
- Indications Glioma
- Focus Therapeutic Use
- Acronyms DIPG
- Sponsors Burzynski Research Institute
- 29 Jan 2018 Planned primary completion date changed from 1 Mar 2019 to 1 Mar 2020.
- 10 May 2016 Status changed from recruiting to active, no longer recruiting.
- 14 Apr 2016 Status changed from planning to recruiting, as per Burzynski Research Institute media release.